| Date | Time | Source | Headline | Symbol | Company |
| 07/11/2024 | 12:21PM | iHub Newswire | FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing | | |
| 01/04/2024 | 8:45AM | PR Newswire (US) | AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies | NYSE:ABBV | AbbVie Inc |
| 01/04/2024 | 8:00AM | PR Newswire (US) | AbbVie to Host Full-Year and Fourth-Quarter 2023 Earnings Conference Call | NYSE:ABBV | AbbVie Inc |
| 01/03/2024 | 6:17PM | Dow Jones News | Abbvie Stock Edges Lower After CVS Says It Will Drop Humira From Some Coverage | NYSE:ABBV | AbbVie Inc |
| 01/03/2024 | 5:59PM | Dow Jones News | CVS Health To Cover Humira Biosimilars April 1 | NYSE:ABBV | AbbVie Inc |
| 01/03/2024 | 5:17PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:ABBV | AbbVie Inc |
| 01/02/2024 | 8:00AM | PR Newswire (US) | AbbVie to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NYSE:ABBV | AbbVie Inc |
| 12/28/2023 | 5:00PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:ABBV | AbbVie Inc |
| 12/26/2023 | 5:02PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:ABBV | AbbVie Inc |
| 12/22/2023 | 4:13PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NYSE:ABBV | AbbVie Inc |
| 12/13/2023 | 11:29AM | Dow Jones News | AbbVie Currently Up 11 Consecutive Days, on Pace for Longest Winning Streak Since December 2021 -- Data Talk | NYSE:ABBV | AbbVie Inc |
| 12/12/2023 | 11:24AM | Dow Jones News | AbbVie Currently Up 10 Consecutive Days, on Pace for Longest Winning Streak Since December 2021 -- Data Talk | NYSE:ABBV | AbbVie Inc |
| 12/12/2023 | 5:50AM | IH Market News | Hasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and More | NYSE:ABBV | AbbVie Inc |
| 12/09/2023 | 12:00PM | PR Newswire (US) | New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) | NYSE:ABBV | AbbVie Inc |
| 12/08/2023 | 10:28AM | Dow Jones News | AbbVie Currently Up Eight Consecutive Days, on Track for Longest Winning Streak Since December 2021 -- Data Talk | NYSE:ABBV | AbbVie Inc |
| 12/08/2023 | 6:23AM | IH Market News | Apple Boosts Vietnam Production, Broadcom Revenue Miss, Stellantis Job Cuts – Latest Updates | NYSE:ABBV | AbbVie Inc |
| 12/07/2023 | 11:48AM | Dow Jones News | AbbVie Currently Up Seven Consecutive Days, on Track for Longest Winning Streak Since December 2021 -- Data Talk | NYSE:ABBV | AbbVie Inc |
| 12/07/2023 | 10:27AM | Dow Jones News | Trending: AbbVie to Buy Cerevel for $45 a Share | NYSE:ABBV | AbbVie Inc |
| 12/07/2023 | 6:23AM | IH Market News | Alphabet Unveils Advanced AI Model, AMD Expects $45 Billion AI Market, Chevron’s $19.5B Investment Plans, BMY Increases Dividend, and More | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 5:28PM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 5:10PM | Dow Jones News | AbbVie to Buy Cerevel Therapeutics for $8.7 Billion -- Update | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 5:05PM | Dow Jones News | AbbVie to Buy Cerevel Therapeutics for $8.7 Billion | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 4:59PM | Dow Jones News | AbbVie Close to $8 Billion Deal for Cerevel Therapeutics, Sources Say, Reuters Reports | NYSE:ABBV | AbbVie Inc |
| 12/06/2023 | 4:30PM | PR Newswire (US) | AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline | NYSE:ABBV | AbbVie Inc |
| 12/05/2023 | 8:45AM | PR Newswire (US) | AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies | NYSE:ABBV | AbbVie Inc |
| 11/30/2023 | 8:47AM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:ABBV | AbbVie Inc |
| 11/30/2023 | 8:42AM | Dow Jones News | ImmunoGen Shares Soar Premarket on Takeover by AbbVie | NYSE:ABBV | AbbVie Inc |
| 11/30/2023 | 8:13AM | Dow Jones News | AbbVie to Buy ImmunoGen for More Than $10 Billion | NYSE:ABBV | AbbVie Inc |
| 11/30/2023 | 7:30AM | PR Newswire (US) | AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio | NYSE:ABBV | AbbVie Inc |
| 11/29/2023 | 10:12AM | Dow Jones News | AbbVie's Experimental Therapy Shows Reduction in Type of Lung Cancer in Phase 2 Study | NYSE:ABBV | AbbVie Inc |